We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celgene Snags Exclusive Option To Buy Acetylon for $1.7 Billion
Celgene Snags Exclusive Option To Buy Acetylon for $1.7 Billion
August 2, 2013
With a $100 million upfront cash payment, biotech giant Celgene has secured an exclusive option to buy Acetylon Pharmaceuticals and its promising oncology candidates for $1.7 billion.